Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 5,518 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Actinic Keratosis
Interventions: Placebo, 5% VDA-1102, 10% VDA-1102; Drug
Lead sponsor: Vidac Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 2 Diabetes Mellitus
Interventions: RO7795081, Semaglutide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more

Conditions: Diabetes
Interventions: Placebo, AGI-1067; Drug
Lead sponsor: AtheroGenics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Stockbridge, Georgia • San Antonio, Texas

Conditions: Cocaine Abuse
Interventions: ALKS 33-BUP, ALKS 33, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Prostate Cancer
Interventions: avodart, Placebo; Drug
Lead sponsor: Bay State Clinical Trials, Inc.; Other
Eligibility: 35 Years to 90 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Alzheimer's Disease, Dementia, Cognition
Interventions: EVP-6124; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 2
States / cities: Delray Beach, Florida • Albuquerque, New Mexico

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more

Conditions: Obesity
Interventions: Placebo, PF-08642534; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Borderline High LDL-cholesterol
Interventions: Ubiquinol, Ubiquinone, Placebo; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 35 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain Associated With Fibromyalgia
Interventions: DS-5565, Pregabalin, Placebo tablet, Placebo capsule; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 92
States / cities: Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 89 more

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Cilofexor, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypercholesterolemia
Interventions: ETC-1002, Placebo, Atorvastatin; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia

Conditions: Pre-Eclampsia, Gestational Hypertension, Superimposed Pre-Eclampsia, Hypertension, Pregnancy-Induced, Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia
Interventions: Hydrochlorothiazide 50mg Tablet, Placebo Tablet; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Austin, Texas • Galveston, Texas

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Rosuvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 54
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Ramelteon and Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 6
States / cities: Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 3 more

Conditions: Acne Vulgaris
Interventions: Tazarotene Cream 0.1%, Tazorac®, Placebo; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more

Conditions: Topical Penile Exposures
Interventions: dapivirine, matched placebo, universal placebo; Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: Lumateperone high dose, Lumateperone low dose, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 41
States / cities: Little Rock, Arkansas • Sacramento, California • Sherman Oaks, California + 32 more

Conditions: Depression
Interventions: Citalopram, Methylphenidate (MPH), Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Methamphetamine Addiction, Crystal Meth Addiction, Amphetamine Addiction
Interventions: Varenicline, then placebo, Placebo, then varenicline; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: HER2 Positive Breast Cancer
Interventions: tucatinib, capecitabine, trastuzumab, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more

Conditions: Scalp Psoriasis
Interventions: DSXS topical, Vehicle topical; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 371 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: atrasentan hydrochloride, docetaxel, prednisone, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 554
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more

Search by objective public record fields.

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity

Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol

Treatment of Pain Associated With Fibromyalgia

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy